Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 148

1.

Sequential ubiquitination of NLRP3 by RNF125 and Cbl-b limits inflammasome activation and endotoxemia.

Tang J, Tu S, Lin G, Guo H, Yan C, Liu Q, Huang L, Tang N, Xiao Y, Pope RM, Rajaram MVS, Amer AO, Ahmer BM, Gunn JS, Wozniak DJ, Tao L, Coppola V, Zhang L, Langdon WY, Torrelles JB, Lipkowitz S, Zhang J.

J Exp Med. 2020 Apr 6;217(4). pii: e20182091. doi: 10.1084/jem.20182091.

PMID:
31999304
2.

Akt-1 and Akt-2 Differentially Regulate the Development of Experimental Autoimmune Encephalomyelitis by Controlling Proliferation of Thymus-Derived Regulatory T Cells.

Ouyang S, Zeng Q, Tang N, Guo H, Tang R, Yin W, Wang A, Tang H, Zhou J, Xie H, Langdon WY, Yang H, Zhang J.

J Immunol. 2019 Mar 1;202(5):1441-1452. doi: 10.4049/jimmunol.1701204. Epub 2019 Jan 28.

PMID:
30692211
3.

Regulation of immune responses by E3 ubiquitin ligase Cbl-b.

Tang R, Langdon WY, Zhang J.

Cell Immunol. 2019 Jun;340:103878. doi: 10.1016/j.cellimm.2018.11.002. Epub 2018 Nov 7. Review.

PMID:
30442330
4.

Cbl Ubiquitin Ligases Control B Cell Exit from the Germinal-Center Reaction.

Li X, Gadzinsky A, Gong L, Tong H, Calderon V, Li Y, Kitamura D, Klein U, Langdon WY, Hou F, Zou YR, Gu H.

Immunity. 2018 Mar 20;48(3):530-541.e6. doi: 10.1016/j.immuni.2018.03.006.

5.

Regulation of C-Type Lectin Receptor-Mediated Antifungal Immunity.

Tang J, Lin G, Langdon WY, Tao L, Zhang J.

Front Immunol. 2018 Feb 1;9:123. doi: 10.3389/fimmu.2018.00123. eCollection 2018. Review.

6.

Hitting the snooze button: Inducing quiescence with the FLT3 inhibitor quizartinib protects hematopoietic progenitors from chemotherapy.

Taylor SJ, Langdon WY.

Mol Cell Oncol. 2017 Sep 19;4(6):e1378156. doi: 10.1080/23723556.2017.1378156. eCollection 2017.

7.

Sleeping through the storm: Preventing myelosuppression with quizartinib.

Taylor SJ, Langdon WY.

Oncotarget. 2017 Sep 30;8(51):88255-88256. doi: 10.18632/oncotarget.21395. eCollection 2017 Oct 24. No abstract available.

8.

Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinib.

Taylor SJ, Duyvestyn JM, Dagger SA, Dishington EJ, Rinaldi CA, Dovey OM, Vassiliou GS, Grove CS, Langdon WY.

Sci Transl Med. 2017 Aug 9;9(402). pii: eaam8060. doi: 10.1126/scitranslmed.aam8060.

PMID:
28794285
9.

Genetically improved BarraCUDA.

Langdon WB, Lam BYH.

BioData Min. 2017 Aug 2;10:28. doi: 10.1186/s13040-017-0149-1. eCollection 2017.

10.

CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies.

Lv K, Jiang J, Donaghy R, Riling CR, Cheng Y, Chandra V, Rozenova K, An W, Mohapatra BC, Goetz BT, Pillai V, Han X, Todd EA, Jeschke GR, Langdon WY, Kumar S, Hexner EO, Band H, Tong W.

Genes Dev. 2017 May 15;31(10):1007-1023. doi: 10.1101/gad.297135.117. Epub 2017 Jun 13.

11.

Inhibition of CBLB protects from lethal Candida albicans sepsis.

Wirnsberger G, Zwolanek F, Asaoka T, Kozieradzki I, Tortola L, Wimmer RA, Kavirayani A, Fresser F, Baier G, Langdon WY, Ikeda F, Kuchler K, Penninger JM.

Nat Med. 2016 Aug;22(8):915-23. doi: 10.1038/nm.4134. Epub 2016 Jul 18.

12.

Targeting CBLB as a potential therapeutic approach for disseminated candidiasis.

Xiao Y, Tang J, Guo H, Zhao Y, Tang R, Ouyang S, Zeng Q, Rappleye CA, Rajaram MV, Schlesinger LS, Tao L, Brown GD, Langdon WY, Li BT, Zhang J.

Nat Med. 2016 Aug;22(8):906-14. doi: 10.1038/nm.4141. Epub 2016 Jul 18.

13.

Dasatinib promotes the activation of quiescent hematopoietic stem cells in mice.

Duyvestyn JM, Taylor SJ, Dagger SA, Langdon WY.

Exp Hematol. 2016 May;44(5):410-421.e5. doi: 10.1016/j.exphem.2016.02.008. Epub 2016 Feb 26.

14.

Human IgG1 antibodies suppress angiogenesis in a target-independent manner.

Bogdanovich S, Kim Y, Mizutani T, Yasuma R, Tudisco L, Cicatiello V, Bastos-Carvalho A, Kerur N, Hirano Y, Baffi JZ, Tarallo V, Li S, Yasuma T, Arpitha P, Fowler BJ, Wright CB, Apicella I, Greco A, Brunetti A, Ruvo M, Sandomenico A, Nozaki M, Ijima R, Kaneko H, Ogura Y, Terasaki H, Ambati BK, Leusen JH, Langdon WY, Clark MR, Armour KL, Bruhns P, Verbeek JS, Gelfand BD, De Falco S, Ambati J.

Signal Transduct Target Ther. 2016;1. pii: 15001. Epub 2016 Jan 28.

15.

Protein Tyrosine Phosphatase SHP-1 Modulates T Cell Responses by Controlling Cbl-b Degradation.

Xiao Y, Qiao G, Tang J, Tang R, Guo H, Warwar S, Langdon WY, Tao L, Zhang J.

J Immunol. 2015 Nov 1;195(9):4218-27. doi: 10.4049/jimmunol.1501200. Epub 2015 Sep 28.

16.

The targeting of human and mouse B lymphocytes by dasatinib.

Oksvold MP, Duyvestyn JM, Dagger SA, Taylor SJ, Forfang L, Myklebust JH, Smeland EB, Langdon WY.

Exp Hematol. 2015 May;43(5):352-363.e4. doi: 10.1016/j.exphem.2015.01.008. Epub 2015 Jan 29.

17.

Performance of genetic programming optimised Bowtie2 on genome comparison and analytic testing (GCAT) benchmarks.

Langdon WB.

BioData Min. 2015 Jan 8;8(1):1. doi: 10.1186/s13040-014-0034-0. eCollection 2015.

18.

E3 Ubiquitin Ligase Cbl-b Regulates Thymic-Derived CD4+CD25+ Regulatory T Cell Development by Targeting Foxp3 for Ubiquitination.

Zhao Y, Guo H, Qiao G, Zucker M, Langdon WY, Zhang J.

J Immunol. 2015 Feb 15;194(4):1639-45. doi: 10.4049/jimmunol.1402434. Epub 2015 Jan 5.

19.

Loss of c-Cbl E3 ubiquitin ligase activity enhances the development of myeloid leukemia in FLT3-ITD mutant mice.

Taylor SJ, Thien CB, Dagger SA, Duyvestyn JM, Grove CS, Lee BH, Gilliland DG, Langdon WY.

Exp Hematol. 2015 Mar;43(3):191-206.e1. doi: 10.1016/j.exphem.2014.11.009. Epub 2014 Dec 19.

20.

Correlating hemodynamic magnetic resonance imaging with high-field intracranial vessel wall imaging in stroke.

Langdon W, Donahue MJ, van der Kolk AG, Rane S, Strother MK.

J Radiol Case Rep. 2014 Jun 30;8(6):1-10. doi: 10.3941/jrcr.v8i6.1795. eCollection 2014 Jun.

Supplemental Content

Loading ...
Support Center